Shampoo bottles recycled into glasses

Australian eyewear manufacturer Dresden Vision is making further advances in environmental sustainability, with the company set to debut what it claims to be the first frames created entirely from recycled shampoo bottles. Read more

Optical Dispensing workshops go nationwide in 2020

The Australasian College of Optical Dispensing (ACOD) will next year offer Certificate IV in Optical Dispensing HLT47815 workshops throughout Australia, with face-to-face sessions now planned for every Australian capital city except Darwin.

As well as the current workshops on offer in Sydney, Hobart, Canberra, Perth and Auckland, in 2020 face-to-face ACOD sessions are planned for Brisbane, Melbourne and Adelaide, pending student numbers.

According to Mr James Gibbins, director and co-founder of ACOD, interest rains high in regionally delivered dispensing training with a student-focussed model. Also, local state subsidies are increasing student numbers while also decreasing both the time out of store and the costs of training.

ACOD offers the Certificate IV in Optical Dispensing HLT47815 course predominantly online, but training is reinforced by several workshops throughout the year. Students also undertake at least 100 hours of work experience in a retail optical dispensary with the support of a workplace supervisor.

The announcement follows the success this year of ACOD’s partnership with the University of Canberra to offer the first locally facilitated dispensing workshops for students ployed in the capital city and its surrounding areas. The local training addressed the frustrations of Canberra-based students, who were forced to travel to Sydney or further to attend workshops.

Glaucoma Australia announces new president

Associate professor Simon Skalicky has been announced as Glaucoma Australia’s (GA) new president as the organisation aims to continue its recent success of reaching the country’s glaucoma patients. Read more

Investors take note of Opthea’s potential

Australian biotech company Opthea has reported a solid cash position to further advance clinical trials of its lead drug candidate OPT-302 in FY20, as it moves closer to imposing itself on the macular disease market. Read more